logo

For the Inventor, By the Inventor

Takatsuki, Japan

Tadaaki Komori

This inventor holds 11 USPTO granted patents. Top assignee: Fujisawa Pharmaceutical Company, Ltd.. Active years: 1977-1990.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tadaaki Komori. Retrieved from https://idiyas.com/inventor/tadaaki-komori

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 100.0

Average Co-Inventor Count = 6.6

ph-index = 3

Forward Citations = 24(Granted Patents)


Location History:

  • Takatsuki, JA (1977)
  • Takatsuki, JP (1978 - 1990)

Company Filing History:

goldMedal11 out of 940 
 
Fujisawa Pharmaceutical Company, Ltd.
 patents

Years Active: 1977-1990

Loading Chart...
11 patents (USPTO):Explore Patents
1. 4950605 - FR-900493 substance, a process for its production and a pharmaceutical (1990-08-21),
2. 4861774 - Method of treating tumors using tetracyclo compounds (1989-08-29),
3. 4743555 - Biologically pure culture of Streptomyces sandaensis No. 6897 (1988-05-10),
4. 4654211 - New compound, FR-900451, production and use thereof (1987-03-31),
5. 4645765 - Tetracyclo compounds and a pharmaceutical composition containing the same (1987-02-24),
6. 4479942 - Tetrahydrofurnancarboxylic acid derivatives, processes for preparation (1984-10-30),
7. 4472300 - Azetidinone derivatives and process for preparation thereof (1984-09-18),
8. 4313935 - Antibiotic FR-900129 substance, a process for the preparation thereof (1982-02-02),
9. 4207234 - 4-Unsubstituted azetidinone derivatives and process for preparation (1980-06-10),
10. 4128546 - Process for the purification of FR-1923 substance (1978-12-05),
11. 4018772 - Process for the purification of bicyclomycin (1977-04-19),

Title: Tadaaki Komori: Pioneering Innovations in Pharmaceutical Science

Introduction

Tadaaki Komori, an accomplished inventor based in Takatsuki, Japan, has made significant contributions to the field of pharmaceutical science, holding a total of 11 patents. His work is characterized by a focus on antimicrobial agents and innovative cancer treatment methods.

Latest Patents

Among his notable patents, Tadaaki Komori has developed the FR-900493 substance, which features a molecular formula of C.sub.20 H.sub.33 N.sub.5 O.sub.11. This compound, recoverable from Bacillus cultures, exhibits antimicrobial activity and shows potential for treating and preventing infectious diseases in both humans and animals. Additionally, he has patented a method for treating tumors, specifically carcinoma or sarcoma, in mammals using tetracyclo compounds. This advancement involves administering an effective amount of a compound that could range in various forms, such as formyl or hydroxymethyl, reflecting his innovative approach to tackling serious health conditions.

Career Highlights

Tadaaki Komori is employed at Fujisawa Pharmaceutical Company, Ltd., where he has been instrumental in advancing pharmaceutical research and development. His career is marked by a commitment to improving health outcomes through scientific exploration and innovation.

Collaborations

Throughout his career, Komori has collaborated with esteemed colleagues such as Masanobu Kohsaka and Masashi Hashimoto. These partnerships have facilitated the exchange of ideas and knowledge, contributing to his success in the patent realm.

Conclusion

Tadaaki Komori continues to exemplify the spirit of innovation in the pharmaceutical industry. His groundbreaking patents not only showcase his dedication to medical science but also highlight the importance of collaboration in achieving significant advancements in treatment options. As he moves forward in his career, his contributions are anticipated to have a lasting impact on public health.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…